The clinical trial biorepository & archiving solution market is expected to generate USD 4,877.7 million in 2024 and is projected to reach a value of USD 13.7 billion by 2034. Forecasts predict that revenue will increase at a CAGR of 10.9% between 2024 and 2034. Industry analysts estimate that the clinical trial biorepository and archiving solution industry generated USD 4,398.2 billion in revenue in 2023.
Best practice guidelines for biorepositories have been issued by the National Cancer Institute (NCI). Federally funded research institutions can refer to these guidelines for recommendations, even though they are not formal regulations. The use of technology has revolutionized biorepository operations, allowing remote monitoring and inspection of operations. Regulatory compliance ensures conformity with accreditation criteria, permits the evaluation of quality methods objectively, and identifies opportunities for improvement in quality methods.
The use of technology has made it easier for biorepositories to integrate with clinical and research networks. The integration of these systems allows for the standardization of operational workflows, the sharing of resources, and the facilitation of seamless collaboration. As a result of technology, standard operating procedures (SOPs) have been developed and implemented. These SOPs must be incorporated into the daily operations of a biorepository in order to reduce variability and ensure the safety and efficiency of biospecimen storage and handling.
Clinical Trial Biorepository & Archiving Solution Industry Assessment
| Attributes | Key Insights |
|---|---|
| Clinical Trial Biorepository & Archiving Solution Market Historical Size, 2023 | USD 4,398.2 million |
| Clinical Trial Biorepository & Archiving Solution Market Estimated Size, 2024 | USD 4,877.7 million |
| Clinical Trial Biorepository & Archiving Solution Market Size, 2034 | USD 13.7 billion |
| Value-based CAGR (2024 to 2034) | 10.9% |
The Health Insurance Portability and Accountability Act (HIPAA) may also have to be observed by biorepositories as relevant regulations. According to HIPAA, all protected health information about patients is kept private and secure. Biorepositories adhere to best practices when managing data, storing samples, and transporting them. In order to improve global biorepository operations, information technology is used to ensure data integrity and analysis of long-term storage needs in clinical trial biorepositories will drive demand.
A high-quality sample and clinical data is obtained by researchers, thus improving the accuracy and reliability of their studies. Research consortia, pharmaceutical corporations, and educational institutions frequently collaborate with biorepositories in order to facilitate joint research activities. Due to their ability to pool resources, knowledge, and biospecimens, collaborations enable large-scale studies and the investigation of a variety of scientific topics.
Biorepositories provide access to biospecimens and related clinical data, which enable researchers to focus their research on rare diseases. Scientists can analyze samples to find biomarkers unique to certain diseases, track illness progression, and assess treatment effectiveness. Biorepositories collect biospecimens over time from people with rare diseases that support longitudinal studies. As a result of these studies, prognostic indicators can be identified, and treatment outcomes can be evaluated over long periods of time.
A biorepository that is integrated or linked to a registry can be used to combine the data of people with uncommon diseases. The pooling of data allows for larger sample sizes, which is vital for epidemiological research and for understanding the incidence, prevalence, and natural history of rare diseases.
By facilitating the development of diagnostics and treatments for uncommon diseases, biorepositories contribute to medical advancements. Researchers can determine the cause of uncommon illnesses by analyzing biospecimens from patients with them, and they can develop treatments that address specific aspects of these illnesses.
Research collaborations between biorepositories and researchers, patient advocacy organizations, and pharmaceutical companies are frequently supported. These partnerships help scientists study uncommon diseases and find cures for them by pooling their knowledge, resources, and biospecimens.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Following is a table that illustrates the predicted CAGR for clinical trial biorepository and archiving solutions over several semi-annual periods from 2024 through 2034. In the first half of the decade (2023-2033), a CAGR of 12.5% is predicted, with a slightly lower growth rate of 12.1% in the second half (H2).
| Particular | Value CAGR |
|---|---|
| H1 | 12.5% (2023 to 2033) |
| H2 | 12.1% (2023 to 2033) |
| H1 | 11.5% (2024 to 2034) |
| H2 | 10.8% (2024 to 2034) |
The annual CAGR is predicted to reach 11.5% in the first half of 2024 and remain relatively low at 10.8% in H2 2034.
Research Activities and New Medications will Fuel the Growth of the Clinical Trial Biorepository & Archiving Solution Market
Green initiatives have been implemented by some stakeholders to reduce the environmental impact of biorepository operations in response to growing concerns regarding sustainability. Utilizing sustainable packaging materials, energy-efficient storage methods, and disposing of samples in a sustainable manner include recycling samples.
As players realize that patient engagement and informed consent are crucial to biobanking, they are adopting tactics to increase participatory knowledge and involvement. Patients and researchers may also communicate through the creation of patient centered permission forms, educational materials, and channels of communication.
To facilitate interoperability and data exchange between clinical trial networks and research institutions, players are aiming to set standards and simplify data formats. The process involves using common data elements (CDEs) to describe clinical and biological data and compiling minimum information about biobanks in accordance with industry standards like the Minimum Information About a Biobank (MIABIS).
The discovery of new treatments and medications, particularly in infectious diseases, neurology, and oncology, has fueled the growth of biorepository services worldwide. Increasing genomic research interest and the need to store large amounts of genetic material has led to the development of advanced biorepository systems for DNA, RNA, and other biomolecules.
Market Trends in Clinical Trial Archiving Solutions
The trend towards digitizing documents and developing automated tools to track and manage samples is a major trend. An automated system ensures better tracking and retrieval of samples, increases efficiency and reduces the chance of human error. The threat of cyberattacks, particularly in the form of hacking, has made it increasingly important to improve data security procedures. Security and integrity of clinical trial data are ensured through the use of blockchain technology, sophisticated access controls, and advanced encryption.
In the wake of the COVID-19 pandemic, decentralized and remote clinical trials have become more prevalent. Biorepositories offer services that allow remote biological sample collection, protection, and transportation to be easier and more efficient. Environmentally sustainable practices are becoming more prevalent in biorepository management, such as energy-efficient equipment, recycling of materials, and innovative storage solutions.
Biorepository solutions are becoming more integrated with bioinformatics capabilities. With this integration, researchers are able to analyze data more effectively, utilize samples more efficiently, and gain a deeper understanding of their findings.
Opportunity for Clinical Trial Biorepository & Archiving Solution
As preclinical products are increasingly needed, especially in personalized and genomic medicine, biorepositories and archiving systems are becoming more in demand. The expansion of biochemical sample management and data preservation is driving this development. Integrating LIMS software to manage laboratory samples improves data management skills. With this integration, data collection and analysis will be more effective and precise, resulting in market growth.
Using modern technologies, such as neural networks, machine learning, and artificial intelligence, to enhance the ability of biorepositories to administer and analyze data is a significant step forward. Data collection and analysis will become more efficient and precise with this integration, resulting in a market boom. Biorepositories and archives that comply with clinical trial data storage regulations are becoming increasingly important. Offering compliance services can add value by ensuring compliance with international regulations.
Regulatory Complexity and High Cost Regarding Clinical Trial Biorepository & Archiving Solution Could Limit Market Growth
Costs for clinical trial biorepository and archiving solutions include refrigeration services, tracking specimen temperatures, inventory management, and equipment management. The lower cost of storage and cold-chain operations may pose a challenge for smaller pharmaceutical companies, so they may seek to outsource these functions in order to maximize their pharmaceutical research and development resources.
To maintain biological samples for an extended period, the clinical trials biorepository should have all the necessary facilities and expertise. This involves adhering to industry best practices in governance, workflow, and specimen handling. Multi-site initiatives can pose challenges in terms of coordinating and standardizing biorepository procedures.
For monitoring the location, use, and condition of samples, tracking them over time is crucial, however, these systems are often difficult to implement and expensive. Biomedical research has become increasingly complex as sports injuries and orthopedic disorders have become more common. Large numbers of samples pose challenges, especially in terms of storage and management.
Principal Consultant
The clinical trial biorepository & archiving solution industry experienced a CAGR of 12.1% during the historical period between 2019 and 2023. The value of the clinical trial biorepository & archiving solution industry increased from USD 2,307.9 billion in 2019 to USD 4,398.2 million in 2023.
Market penetration of digital archiving solutions in clinical trial management has become more prevalent in biorepositories, and security and privacy have improved. The deployment of robust cyber security measures and adherence to regulations such as HIPAA (Health Insurance Portability and Accountability Act) can help protect the privacy of patients as well as sensitive information that is processed by the organization.
Technological advancements have enabled the development of methods to store samples that maintain their integrity. Temperature regulation and light protection can be achieved using modern refrigeration and monitoring systems. A variety of technologies, such as barcodes and RFID, have revolutionized the tracking of samples in biorepositories. The ability to track samples precisely and effectively with the help of these systems further reduces the possibility of errors and contributes to increased productivity.
Biorepositories are using database and informatics systems to manage data efficiently. The information related to biospecimens can be tracked, managed, and retrieved with the help of such systems, making it easy to access and organize. As a result of the creation of digital inventory platforms, sample storage has become simpler and more efficient. Data on these platforms can be securely stored, documents can be easily edited, and monitoring can be integrated into the process, improving sample integrity, safety, efficacy, and security.
The top tier 1 companies hold a 45.7% share of the global market. Due to their global reach, extensive service offerings, and robust infrastructure, the tier 1 players dominate the market. Biorepositories and archiving solutions under their control set the industry standard for quality and innovation.
Players offer a wide range of services, from clinical trial management to biorepository solutions. They utilize an extensive global network and advanced technologies to offer innovative solutions to meet the needs of clients. Prominent companies in Tier 1 include LabCorp Drug Development and Charles River Laboratories.
In Tier 2, mid-sized players hold 29.7% of the market share and hold a strong influence in particular regions. Several Tier 2 players are expanding rapidly, gaining market share, and becoming more competitive. Although these companies usually offer high-quality services and have close client relationships, their global network may not be as extensive as that of Tier 1 players. Personalized medicine treatments are provided by the organization as part of its customized biorepository service. Tier 2 companies include Q2 Solutions, Medpace, and Precision for Medicine, Inc.
In Tier 3, the majority of companies are small businesses serving niche markets. Tier 3 companies typically supply Tier 2 companies with raw materials or basic components. A Tier 3 player specializes in niche markets and caters to specialized needs. Although they may excel in certain fields, they are not able to influence the market as much as higher-tier firms. Players include Brooks Life Science, ATCC, Labconnect, Patheon, and Cell&Co BioServices.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
An overview of two industries within the healthcare division is provided below, namely, Clinical Trials and Rare Diseases Clinical Trials. The following tables can help potential clients make smart funding and research decisions.
Clinical Trials Industry Assessment:
The clinical trials market is anticipated to expand at a CAGR of 4.3% from 2024 to 2034. As part of medical research, clinical trials are conducted with the aim of advancing medical knowledge and improving patient care. Phase-by-phase assessments are conducted in order to assess side effects, dosage, and effectiveness. A close health monitoring program ensures that ethical standards and the participants' safety are met. As a result of a successful trial, new standard treatments can be developed, leading to improved outcomes for patients throughout the world.
| Attributes | Description |
|---|---|
| Related Market | Clinical Trials Market |
| CAGR (2024 to 2034) | 4.3% |
| Growth Factor | Government funding and new drug developments. |
| Key Trend | Virtual clinical trials and predictive analytics are key trends. |
Rare Disease Clinical Trials Industry Assessment:
The growth of the rare disease clinical trials market is supported by the growing demand from healthcare sectors, which is poised to expand at a CAGR of 9.7% from 2023 to 2033. Clinical trials for rare diseases are likely to experience improved success as advanced genetic research, genetic testing, and data analytics are applied. Trial designs that are innovative, such as adaptive trials and decentralized trials, have the potential to be highly efficient. The development of targeted therapies can be accelerated with increased collaboration among stakeholders and regulatory support.
| Attributes | Description |
|---|---|
| Related Market | Rare Disease Clinical Trials Market |
| CAGR (2023 to 2033) | 9.7% |
| Growth Factor | Development of new rare disease treatments and advances in genomics. |
| Key Trend | Use of precision medicine and focus on gene therapies. |
Rare Disease Clinical Trials Industry Assessment:
The growth of the rare disease clinical trials market is supported by the growing demand from healthcare sectors, which is poised to expand at a CAGR of 9.7% from 2023 to 2033. Clinical trials for rare diseases are likely to experience improved success as advanced genetic research, genetic testing, and data analytics are applied. Trial designs that are innovative, such as adaptive trials and decentralized trials, have the potential to be highly efficient. The development of targeted therapies can be accelerated with increased collaboration among stakeholders and regulatory support.
| Attributes | Description |
|---|---|
| Related Market | Rare Disease Clinical Trials Market |
| CAGR (2023 to 2033) | 9.7% |
| Growth Factor | Development of new rare disease treatments and advances in genomics. |
| Key Trend | Use of precision medicine and focus on gene therapies. |
Detailed market analyses of Clinical Trial Biorepository & Archiving Solution markets are provided for different countries. Global market demand is analyzed for a variety of regions, including North America, Asia Pacific, Europe, and others. Canada is expected to keep its place at the forefront in North America, exhibiting a CAGR of 5% from 2024 to 2034. In Asia Pacific, India is anticipated to experience a CAGR of 10.5% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.9% |
| Canada | 5% |
| United Kingdom | 3.3% |
| Germany | 2.9% |
| India | 10.5% |
| China | 9.2% |
| South Korea | 7.3% |
The United States industry predicted a 2.9% CAGR for the forecast period. With the advancement of drug development, personalized medicine, and the need for more data, the number of clinical trials conducted in the United States has risen. In the medical industry, technological advancements and advances are expected to drive demand for these solutions and services.
Increasing numbers of clinical trials, industry participation, and the introduction of medical trials are contributing to the research development in this country. A rising adoption of digital technologies and an increasing focus on preserving user data will increase demand in the market. Cloud computing, blockchain, and artificial intelligence will become more popular in the medical field. It is expected that the demand for medical technologies will increase as telemedicine and telehealth become more prevalent.
Significant growth is expected in the United Kingdom market over the next few years. A CAGR of 3.3% is projected for the market over the forecast period. A number of organizations and service providers in the United Kingdom provide clinical trial archiving and biorepository services. These suppliers manage, store, and track clinical study samples and documentation appropriately. In addition to following legal guidelines, they provide the infrastructure and resources needed to preserve samples for long periods of time.
Clinical research specimen integrity can be enhanced through the use of a central biorepository in multi-site clinical trials. By implementing standardized operational workflows and procedures, a central biorepository ensures a uniform approach to the processing, storage, and evaluation of biospecimens throughout the organization.
The Clinical Trials Regulations, in particular Regulation 31A of the Medicines for Human Use (Clinical Trials) Amendment Regulations 2006, define the archiving requirements for Clinical Trials of Investigational Medicinal Products (CTIMPs).
The clinical trial biorepository & archiving solution market in India is showing positive growth. The market in India is likely to expand at a CAGR of 10.5% from 2024 to 2034. A biorepository and archive solution is critical for managing and storing clinical samples and data efficiently. India has several organizations that provide services that meet international standards.
A significant improvement in life expectancy and a reduction in infant mortality has occurred in India in recent years. A combination of increasing government funding and a developing healthcare infrastructure is likely to create a market in the near future. A total of 1,50,000 government-funded healthcare and wellness centers are being created by the Indian government in a bid to improve India's healthcare infrastructure. Growth in the healthcare market will be supported by rising investments in infrastructure improvement.
Information about the industry's leading segments is provided in this section. The clinical products segment contributed 85.4% of the value share in 2023. Based on the application, biorepository services held a market share of 73.6% in 2023.
| Type | Clinical Products |
|---|---|
| Value Share (2023) | 85.4% |
The clinical products segment held a market share of over 85.4% in 2023. An analysis kit is a pre-packaged set of materials that contain the necessary materials for collecting, storing, and analyzing biological samples. These kits ensure standard and consistent sample collection across a wide range of studies and sites. Regulatory compliance tools like GCP, GLP, and 21 CFR Part 11 make sample storage and data management easier.
According to ClinicalTrials.gov, 386,583 studies had been registered in 219 countries by August 2021. According to the data, 362,524 tests were conducted in 2020, and 325,787 tests were conducted in 2019. Stimwave Technology is being advanced through the level-1 FREEDOM clinical research series, which includes randomized trials monitoring the responses of chronic pain patients over time to peripheral nerve stimulation (PNS). In FREEDOM-1, the company is evaluating the Stimwave Freedom PNS device for the treatment of chronic knee pain in patients.
| Application | Biorepository Services |
|---|---|
| Value Share (2023) | 73.6% |
Revenue from biorepository services accounted for 73.6% of market share in 2023. In biorepository solutions, inventory management systems are key components for tracking and monitoring quantities, locations, and conditions of samples. It eliminates the potential for sample loss or misplacing and ensures that samples are recovered effectively.
A biorepository can offer sample distribution and analysis services, which may include aliquoting, centrifugation, and labeling of samples. The service of managing biorepository data is included in the range of services offered by the biorepository, which covers the clinical data, administration of sample metadata, and consent documents. Regulatory compliance, data integrity, and confidentiality can be assured by implementing secure data management solutions.
A biorepository solution involves retrieving and delivering samples to researchers or other laboratories for further examination. Sample tracking, packaging, and shipping are all necessary to maintain sample integrity during transportation. Clinical study providers could offer customized biorepository services to meet the unique needs of each study. To accomplish this, data management systems, sample collection kits, and storage methods can be created.
Many companies are taking tactical measures to improve their services, including geographic expansion, business partnerships, mergers and acquisitions, and new business contracts.
Recent Industry Developments in Clinical Trial Biorepository & Archiving Solution Market
In terms of product type, the industry is classified into preclinical products and clinical products.
In terms of phase, the industry is segregated into phase I, phase II, phase III, and phase IV.
In terms of application, the market is segmented into biorepository services and archiving solution services.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East and Africa have been covered in the report.
The Clinical Trial Biorepository & Archiving Solution sector is expected to register a CAGR of 10.9% between 2024 and 2034.
The Clinical Trial Biorepository & Archiving Solution market was valued at USD 4,398.2 million in 2023.
The Clinical Trial Biorepository & Archiving Solution industry is expected to generate USD 13.7 billion by 2034 end.
India is expected to record the highest CAGR of 10.5% in the assessment period.
The key players operating in the Clinical Trial Biorepository & Archiving Solution industry include Brooks Life Science, Patheon, Precision for Medicine, Inc., and Medpace.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. Product Type 5.2. Phase 5.3. Application 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type 6.1. Preclinical Products 6.2. Clinical Products 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Phase 7.1. Phase I 7.2. Phase II 7.3. Phase III 7.4. Phase IV 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 8.1. Biorepository Services 8.2. Archiving Solution Services 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. South Asia 9.5. East Asia 9.6. Eastern Europe 9.7. Middle East & Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Product Type, Phase, and Application for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Brooks Life Science 19.2. Patheon 19.3. Precision for Medicine, Inc. 19.4. Medpace 19.5. LabCorp Drug Development 19.6. ATCC 19.7. Q2 Solutions 19.8. Labconnect 19.9. Charles River Laboratories 19.10. Cell&Co BioServices
Explore Healthcare Insights
View Reports
Clinical Trial Biorepository & Archiving Solution Market
